BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. DPZ
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
(NASDAQ: BIVI) Delayed: 1.94 --0 (-0%)
Previous Close $1.94    52 Week High $0.40 
Open $1.94    52 Week Low $0.17 
Day High $1.94    P/E N/A 
Day Low $1.94    EPS $0.00 
Volume 6,706